PMCB
PharmaCyte Biotech, Inc.

Kenneth L. Waggoner commenced employment with PharmaCyte in September 2013. He became the Chief Executive Officer and President in November 2013. Shortly thereafter, Mr. Waggoner assumed the additional position of General Counsel. Mr. Waggoner serves as Chairman of the Board. Mr. Waggoner has over four decades of experience in management, business, operations and the practice of law. Mr. Waggoner began his professional career as an attorney in private practice in 1973 with the law firm of Lawler, Felix & Hall. From 1986 to 2005, he was a senior partner with Brobeck, Phleger and Harrison, where he was the Managing Partner of Brobeck's Los Angeles office. Brobeck provided services to biotechnology clients such as Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. While at Brobeck, Mr. Waggoner served as a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck's worldwide operations with annual revenues in excess of $750,000,000. Mr. Waggoner was the co-Chairman of Brobeck's worldwide Environmental Law Group. Mr. Waggoner's career included leadership and legal positions with Fortune 100 companies most of his professional career. From 2005 to 2007, Mr. Waggoner served as the Vice President and General Counsel of Chevron's global downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.

Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech and is a member of PharmaCyte's Board of Directors. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has 35 years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors. Mr. Trujillo has been the Chief Financial Officer for both privately-held and publicly-traded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports. Mr. Trujillo received his Bachelor's Degree in Accounting in 1982 from California State University, Fullerton.

Gerald W. Crabtree, Ph.D. is the Chief Operating Officer of PharmaCyte. He also services as a Director. Dr. Crabtree has over 50 years of experience in the biomedical sciences sector, having been involved with various pharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates. prepared clinical protocols, Dr. Crabtree served as the Director of Project Planning and Management (Oncology and Immunology) at Bristol-Myers Squibb from 1990 to 1997. While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval. He also served as Project Manager for the development of the major anticancer agent, Taxol, the "number one" drug under development at BMS at that time. Taxol ultimately became a multi-billion dollar drug for BMS and is still widely used to treat a variety of cancers. From 1989 to 1990, Dr. Crabtree was Director of Pharmacology at Viratek, Inc., a subsidiary of ICN Pharmaceuticals, Inc. in Costa Mesa, California, where he worked on the development of anticancer drugs first developed at the Nucleic Acid Research Institute, a joint venture between Eastman Kodak and ICN Pharmaceuticals. He also coordinated the development of ribavirin (Virazole), Viratek's landmark antiviral drug.

Kenneth L. Waggoner commenced employment with PharmaCyte in September 2013. He became the Chief Executive Officer and President in November 2013. Shortly thereafter, Mr. Waggoner assumed the additional position of General Counsel. Mr. Waggoner serves as Chairman of the Board. Mr. Waggoner has over four decades of experience in management, business, operations and the practice of law. Mr. Waggoner began his professional career as an attorney in private practice in 1973 with the law firm of Lawler, Felix & Hall. From 1986 to 2005, he was a senior partner with Brobeck, Phleger and Harrison, where he was the Managing Partner of Brobeck's Los Angeles office. Brobeck provided services to biotechnology clients such as Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others. While at Brobeck, Mr. Waggoner served as a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck's worldwide operations with annual revenues in excess of $750,000,000. Mr. Waggoner was the co-Chairman of Brobeck's worldwide Environmental Law Group. Mr. Waggoner's career included leadership and legal positions with Fortune 100 companies most of his professional career. From 2005 to 2007, Mr. Waggoner served as the Vice President and General Counsel of Chevron's global downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.

Thomas Liquard was appointed to the Board in April 2015. Mr. Liquard has more than a decade of experience in the pharmaceutical industry, having held various commercialization, product development and leadership roles with large pharmaceutical and biotechnology companies. He is currently the CEO of Immuron, a Melbourne-based pharmaceutical company. Prior to Immuron, Mr. Liquard served as the CEO and COO of Alchemia, a major Australian pharmaceutical company. Mr. Liquard spent seven years with Pfizer, Inc. based in New York, where he held various senior commercial positions. His last was as Senior Director, Portfolio Development Leader and Emerging Markets for the Established Products portfolio. In that role, Mr. Liquard drove business development (M&A, licensing, partnerships) and internal product development initiatives.

Dr. Abecassis is the Dean of the University of Arizona College of Medicine - Tucson. Formerly, he was the Director of the Comprehensive Transplant Center of the Feinberg School of Medicine. He was also the Chief of Transplant Surgery in the Department of Surgery at Feinberg and a James Roscoe Miller Distinguished Professor of Medicine at Feinberg. Dr. Abecassis received his Medical Degree from the University of Toronto in 1983 and was awarded a Master of Business Administration degree from the Kellogg School of Management at Northwestern University in 2000. After his postgraduate tenure in Toronto, Dr. Abecassis began his clinical career as Assistant Professor of Surgery and Director of Liver Transplantation and Hepatobiliary Surgery at the University of Iowa. In 1993, Dr. Abecassis became Northwestern University's Director of Liver Transplantation, where he initiated Northwester's liver transplant program. In 2004, Dr. Abecassis was named Chief of the Division of Transplantation at the Feinberg School of Medicine. He became Founding Director of the Comprehensive Transplant Center at Northwestern in 2009 and was appointed Dean for Clinical Affairs at the Feinberg School of Medicine in 2008, serving until 2011.

Gerald W. Crabtree, Ph.D. is the Chief Operating Officer of PharmaCyte. He also services as a Director. Dr. Crabtree has over 50 years of experience in the biomedical sciences sector, having been involved with various pharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates. prepared clinical protocols, Dr. Crabtree served as the Director of Project Planning and Management (Oncology and Immunology) at Bristol-Myers Squibb from 1990 to 1997. While at BMS, Dr. Crabtree established and directed a department that monitored and coordinated the development of all oncologic and immunologic drugs from initial discovery through regulatory approval. He also served as Project Manager for the development of the major anticancer agent, Taxol, the "number one" drug under development at BMS at that time. Taxol ultimately became a multi-billion dollar drug for BMS and is still widely used to treat a variety of cancers. From 1989 to 1990, Dr. Crabtree was Director of Pharmacology at Viratek, Inc., a subsidiary of ICN Pharmaceuticals, Inc. in Costa Mesa, California, where he worked on the development of anticancer drugs first developed at the Nucleic Acid Research Institute, a joint venture between Eastman Kodak and ICN Pharmaceuticals. He also coordinated the development of ribavirin (Virazole), Viratek's landmark antiviral drug.

Dr. Tong serves as Chief Executive Officer of Harmony Medical Inc., an Asian investment group active in the introduction and distribution of medical and healthcare products and services in China and throughout Asia. He is also Chairman of the Business Development Committee of Shanghai Kedu Healthcare Group, the largest medical equipment third-party service provider in China, representing products from GE, Philips, Siemens, Kodak and other multi-nationals as well as local companies. Dr. Tong is the founding Director and Chief Executive Officer of VetCell Therapeutics Asia, a cell therapy company focused on providing cell-based treatments for use in veterinary medicine in Asia. Dr. Tong received his medical degree from the University of Toronto in Ontario, Canada in 1983. He also received a Ph.D. degree in neurophysiology and an M.B.A. degree.

Carlos A. Trujillo serves as the Chief Financial Officer of PharmaCyte Biotech and is a member of PharmaCyte's Board of Directors. Mr. Trujillo is a Certified Public Accountant licensed by the State of California. He has 35 years of experience in finance, accounting and management. Mr. Trujillo started his career in public accounting and was the manager of an audit department. Mr. Trujillo then established a consulting and accounting practice which he operated for ten years and provided services as the Chief Financial Accountant to numerous organizations in several different industries. His experience has extended to companies in the biotechnology, telecommunications, manufacturing, construction and real estate development sectors. Mr. Trujillo has been the Chief Financial Officer for both privately-held and publicly-traded, multinational companies. He brings extensive experience to PharmaCyte in preparing and filing periodic reports with the Securities and Exchange Commission, in mergers and acquisitions and in the filing of comprehensive financial statements and reports. Mr. Trujillo received his Bachelor's Degree in Accounting in 1982 from California State University, Fullerton.

Thomas C. K. Yuen was appointed to the Board in May 2017. Mr. Yuen has more than three decades of experience in entrepreneurship and business leadership, including in the biotech industry. Mr. Yuen co-founded Irvine-based AST Research, Inc. (AST) in 1981. AST was an early pioneer of the computer industry, and the company has been referred to as “the flagship of innovation in the PC era.” Mr. Yuen served as AST's Co-Chairman and Chief Operating Officer from August 1987 to June 1992. Mr. Yuen left AST in 1992 and focused his efforts on investing in new projects. Mr. Yuen served in various engineering and project management positions with Hughes Aircraft Company, Sperry Univac and Computer Automation. Later in his career, Mr. Yuen became Chairman and CEO of SRS Labs, a world leader in audio and voice technology. Currently, Mr. Yuen is Chairman and Chief Executive Officer of PrimeGen Biotech, a private cell therapy company he founded in 2002.